Ann: Biota and Nabi Announce Proposed Merger , page-17

This is looking worse and worse


Nabi Biopharmaceuticals (NABI )

Price at the time of this scan $1.79

Nabi Biopharmaceuticals failed to deliver at nicotine addiction- one of their core business areas. Last month, the firm announced that thier NicVAX (Nicotine Conjugate Immunotherapeutic) did not meet its primary endpoint in the company's second of two confirmatory Phase III clinical trials.

Raafat Fahim, President and Chief Executive of Nabi Biopharmaceuticals, said that the Board of Directors had retained Piper Jaffray to assist with its exploration of the strategic alternatives available to the company to enhance shareholder value. This includes but is not limited to joint ventures, strategic alliances, recapitalization, the sale or merger of all or part of the company or liquidation. Our goal is to move expeditiously to maximize the value of the company's assets while continuing our effort to reduce our operating expenses.

We're not saying this would be a great investment, in fact, this is now purely a very risky speculative play but it could certainly be worth watch-listing for developments from the sidelines as a day trade. Shares have been flat for some time with very little downside left and could see a boost on news as it relates to the possibilities now being explored by the company.

http://seekingalpha.com/article/312289-5-healthcare-stocks-under-5-poised-to-rise



Nice to be Piper Jaffery, paid by both sides.